[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9302681A - Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv. - Google Patents

Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.

Info

Publication number
MX9302681A
MX9302681A MX9302681A MX9302681A MX9302681A MX 9302681 A MX9302681 A MX 9302681A MX 9302681 A MX9302681 A MX 9302681A MX 9302681 A MX9302681 A MX 9302681A MX 9302681 A MX9302681 A MX 9302681A
Authority
MX
Mexico
Prior art keywords
compounds
aids
quinazolins
new
transcriptase inhibitors
Prior art date
Application number
MX9302681A
Other languages
English (en)
Inventor
Terry A Lyle
Thomas J Tucker
Catherine M Wiscount
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MX9302681A publication Critical patent/MX9302681A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos que tienen un núcleo quinazolin-2-ona con un alquinilo substituído o alquenilo substituído en la posición-4. Estos compuestos son útiles para inhibir transcriptasa inversa HIV (incluyendo sus variedades resistentes), la prevención o tratamiento de infección por HIV t el tratamiento de SIDA (síndrome de inmunodeficiencia adquirida, AIDS), ya sea como compuestos, sales farmacéuticamente aceptable, ingredientes de composición farmacéutica, ya en combinación o no con otros antivirales, inmunomoduladores, antibióticos o vacunas. También se describen métodos para tratar SIDA y métodos para evitar o tratar infección por HIV.
MX9302681A 1992-05-07 1993-05-06 Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv. MX9302681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88011992A 1992-05-07 1992-05-07
US99116492A 1992-12-16 1992-12-16

Publications (1)

Publication Number Publication Date
MX9302681A true MX9302681A (es) 1994-05-31

Family

ID=27128564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302681A MX9302681A (es) 1992-05-07 1993-05-06 Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.

Country Status (15)

Country Link
EP (2) EP0639184A1 (es)
JP (1) JPH0813805B2 (es)
KR (1) KR950701322A (es)
CN (1) CN1085550A (es)
AU (2) AU4220493A (es)
BG (1) BG99149A (es)
CA (1) CA2095194A1 (es)
CZ (1) CZ272494A3 (es)
FI (1) FI945199A (es)
HR (1) HRP930857A2 (es)
HU (1) HUT71401A (es)
IL (1) IL105551A0 (es)
MX (1) MX9302681A (es)
SI (1) SI9300244A (es)
WO (1) WO1993022292A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone
US6124302A (en) * 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
HRP980143A2 (en) * 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
EP1091939A1 (en) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
CA2370141A1 (en) 1999-05-26 2000-12-07 James D. Rodgers 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
EP1189882A1 (en) * 2000-04-25 2002-03-27 SAMSUNG ELECTRONICS Co. Ltd. Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
US7119111B2 (en) * 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
JP5470043B2 (ja) * 2007-10-05 2014-04-16 Ｍｓｄ株式会社 ベンゾオキサジノン誘導体
CN101544630B (zh) * 2009-05-13 2013-03-13 中国科学院广州生物医药与健康研究院 羟基化茚地那韦的制备方法
WO2017003724A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL147140B (nl) * 1968-11-26 1975-09-15 Farmaceutici Italia Werkwijze voor het bereiden van geneesmiddelen met een remmende werking op het centrale zenuwstelsel.
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1993022292A1 (en) 1993-11-11
JPH0813805B2 (ja) 1996-02-14
JPH069578A (ja) 1994-01-18
HRP930857A2 (en) 1995-06-30
CN1085550A (zh) 1994-04-20
FI945199A0 (fi) 1994-11-04
IL105551A0 (en) 1993-08-18
CA2095194A1 (en) 1993-11-08
AU3841393A (en) 1993-11-11
BG99149A (en) 1995-06-30
CZ272494A3 (en) 1995-10-18
SI9300244A (sl) 1993-12-31
KR950701322A (ko) 1995-03-23
HUT71401A (en) 1995-11-28
EP0569083A1 (en) 1993-11-10
AU4220493A (en) 1993-11-29
EP0639184A1 (en) 1995-02-22
FI945199A (fi) 1994-11-04

Similar Documents

Publication Publication Date Title
MX9204720A (es) Derivados de quinazolina como inhibidores de transcriptasa inversa de vih.
MY109834A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
ES2125251T3 (es) Inhibidores de la proteasa del vih.
MX9204454A (es) Derivados de tiourea para inhibir la replicacion del virus de inmunodeficiencia humana y formulado farmaceutico que los contiene.
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
DE60036961D1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
ES2174921T3 (es) Inhibidores de la proteasa del vih.
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
AR002957A1 (es) Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen.
AR013758A1 (es) Terapia de combinacion para el tratamiento de sida.
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.
ES2190456T3 (es) Combinacion de inhibidores de la proteasa del vih.
ES2065951T3 (es) Uso de un inhibidor de prolilendopeptidasa para el tratamiento del sida.
ECSP961660A (es) Terapia combinada para infeccion por vih
KR900002787A (ko) 인체 후천성 면역부전증후군 바이러스 감염 저해제
ECSP982741A (es) Terapia combinada para el tratamiento del sida
MX9304351A (es) Inhibidores de proteasas de aminodiol y composiciones farmaceuticas que los incluyen.
DOP2001000263A (es) Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de la integrasa de vih